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Abstract
Objective—Activation of the renal renin-angiotensin system in patients with diabetes mellitus 
appears to contribute to the risk of nephropathy. Recently it has been recognized than an elevation 
of prorenin in plasma also provides a strong indication of risk of nephropathy. This study was 
designed to examine renin-angiotensin system control mechanisms in the patient with diabetes 
mellitus.
Methods—We enrolled 43 subjects with Type 2 diabetes mellitus and, after an acute exposure to 
captopril (25 mg), randomized them to treatment with either irbesartan (300 mg) or aliskiren (300 
mg) for two weeks.
Results—All agents acutely lowered blood pressure and plasma aldosterone, and increased renal 
plasma flow and glomerular filtration rate. Yet only captopril and Aliskiren acutely increased 
plasma renin and decreased plasma angiotensin II, while Irbesartan acutely affected neither renin 
nor angiotensin II. Plasma renin and angiotensin II subsequently did increase upon chronic 
irbesartan treatment. When given on day 14, irbesartan and aliskiren again induced the above 
hemodynamic, renal and adrenal effects, yet without significantly changing plasma renin. 
Irbesartan at that time did not affect plasma angiotensin II, while aliskiren lowered it to almost 
zero.
Conclusions—The relative resistance of the renal renin response to acute (irbesartan) and 
chronic (irbesartan and aliskiren) renin-angiotensin system blockade supports the concept of an 
activated renal renin-angiotensin system in diabetes, particularly at the level of the 
juxtaglomerular cell, and implies that diabetics require higher doses of renin-angiotensin system 
blockers to fully suppress the renal renin-angiotensin system.
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Introduction
Diabetes mellitus is the leading cause of nephropathy and end-stage renal disease in the 
Western world. Abnormalities involving renal perfusion and the renin-angiotensin system 
(RAS) appear to play an important pathogenic role, but the responsible mechanisms remain 
obscure [1–4]. A reduction in renal plasma flow (RPF) is common, accompanied by blunting 
of the renovascular response to angiotensin (Ang II) [1–4]. There is also an accentuated 
renal vasodilator response to angiotensin-converting enzyme (ACE) inhibition, which in turn 
corrects the blunting of responsiveness to Ang II. All of these observations suggest 
activation of the RAS in patients with diabetes mellitus. As plasma renin often is reduced in 
such patients, the findings suggest that it is the intrarenal RAS that is activated [1,5]. Despite 
being low, plasma renin is an independent predictor of cardiovascular events in patients with 
diabetes [6–7]. The rise in plasma renin following RAS blockade is taken to be an indication 
of the degree of RAS blockade [8]. Importantly, the renin rise following acute exposure to 
increasing doses of the Ang II type 1 receptor blocker irbesartan in diabetics is blunted and 
slow as compared to non-diabetic healthy controls, and for a given renin rise a higher 
irbesartan dose was required in diabetics [1]. Yet, simultaneously, the RPF response to 
irbesartan was enhanced in diabetics vs. controls at all irbesartan doses tested [1]. Finally, 
the plasma levels of renin’s precursor, prorenin, are elevated in diabetes, and these elevated 
levels provide a strong indication of risk of the microvascular complications of this disease, 
i.e., nephropathy and retinopathy [9–11].
To obtain a better understanding of the dysregulation of the RAS in diabetes, in the present 
study we carefully compared, in subjects with diabetes, the changes in plasma RAS 
parameters with the hemodynamic, renal and adrenal responses induced by blockade at the 
level of renin, ACE and the Ang II type 1 (AT1) receptor, both acutely and chronically. 
Doses of the 3 types of RAS blockers were chosen in such a manner that identical 
hemodynamic and renal responses could be expected, to rule out changes in plasma RAS 
parameters due to systemic or renal hemodynamic differences [12–14]. In addition, subjects 
were exposed to a high-salt diet to minimize the contribution of the systemic RAS.
Methods
Study protocol
Forty-three subjects with Type 2 diabetes mellitus (29 men, 14 women) averaging 57 years 
of age were studied on a high-sodium diet (Table 1). Fifty-eight percent were White and 
30% were Black. All had hypertension, which was generally well controlled. Most were 
obese (weight 105±4 kg, body mass index 34.8±1.2 kg/m2). After an outpatient evaluation, 
which included history, physical examination, screening chemistry, and hematology 
laboratory tests, all subjects were studied during an 8-day admission to a metabolic ward, 
the Center for Clinical Investigation of the Brigham and Women’s Hospital. Written, 
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informed consent was obtained from each patient, and the protocol was approved by the 
Human Subjects IRB Committee of the Institution.
The subjects were placed on a high-sodium, constant isocaloric diet throughout the study 
and consumed 200 mmol of sodium daily, the first several days as outpatients. Daily dietary 
potassium (100 mmol) and fluid intake (2500 mL) were constant. Twenty-four-hour urine 
samples were collected daily; urinary sodium matched sodium intake usually by days 3 to 5. 
On the first study each subject received the ACE inhibitor captopril at a dose that is at the 
top of the dose-response relationship (25 mg). On the next day, the subjects were 
randomized to receive either the AT1 receptor blocker (ARB) irbesartan (300 mg) or the 
renin inhibitor aliskiren (300 mg). The subjects were then discharged to be readmitted on 
day 14 for a follow-up study on the same drug. Each had received 14 days of treatment. 
Exposure to captopril was open, but exposure to aliskiren and irbesartan were randomized 
and blinded. Phlebotomy limitations prevented subjects from undergoing more than 3 
studies each.
Studies began at 7 am. Subjects had been recumbent and fasting overnight and remained 
recumbent throughout the study. RPF was measured by the clearance of para-
aminohippurate(PAH; Clinalfa, Laufelfmgen, Switzerland) and glomerular filtration rate 
(GFR) by the clearance of inulin (Inutest Polyfructosan, Fresenius Pharma, Linz, Austria) by 
autoanalyzer methods described previously [15]. After a 60-minute control period to 
establish basal RPF, the drug was dosed by mouth.
Blood pressure during each infusion was recorded by an automatic recording device 
(Dinamap, Critikon Inc, Tampa, FL, USA) at 15-minute intervals. Blood pressure fall was 
analyzed from the lowest single blood pressure reached after each dose compared with the 
mean of 4 measures taken at the pre-dose baseline on that study day.
Blood samples and biochemical measurements
Blood samples were collected on ice at the start of the PAH infusion, at 90-minute intervals 
throughout, at the end of each study. Samples were spun immediately, and the plasma was 
frozen until the time of assay. PAH was measured by an autoanalyzer technique [16]. Renin 
concentration was measured with a commercial immunoradiometric kit (Renin III, Cisbio, 
Gif-Sur-Yvette, France) [17]. Total renin concentration was determined simultaneously with 
the same kit after the induction of a conformational change in the prorenin molecule with 
aliskiren (10 µmol/L for 48 hours at 4°C), which enabled its recognition by the active site-
directed radio labeled antibodies applied in the Cisbio kit [18]. Subtraction of the renin 
concentration from the total renin concentration yielded the estimated prorenin 
concentration. Plasma renin activity (PRA) was measured by the trapping of generated Ang 
I by high-affinity antibodies and by subsequent radioimmunoassay. Plasma Ang I and II 
were measured specifically by radioimmunoassay after solid-phase extraction and 
subsequent high-performance liquid chromatography separation [12].
Statistical Analysis
Peak response was taken as the average of the 2 highest consecutive values for PAH/inulin 
clearance and compared with baseline clearance at the beginning of day 1 of the study. The 
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median value was employed. Linear mixed models were used to model response with an 
unstructured covariance for the correlation within subjects. An F test is presented for the 
overall significance of the linear mixed model. For all comparisons, group means have been 
presented with the SEM as the index of dispersion, and an α-level of 0.05 was used to 
determine statistical significance. All analyses were performed in SAS version 9.1. All of 
the hormone measurements were highly skew, but the findings and conclusions were not 
altered through the use of geometric means and examination of the data by non-parametric 
tests.
Results
The patients treated with irbesartan or aliskiren were well-matched for age, racial 
distribution, blood pressure, body habitus, and frequency or severity of obesity (Table 1). 
They were also well matched for physiologic variables, both hemodynamic and hormonal. 
They were somewhat less matched for gender and glycemic control, but no difference 
achieved statistical significance.
As expected, both systolic and diastolic blood pressure decreased following acute and 
chronic exposure to the blockers (Figure 1). The acute responses were identical for all 3 
blockers, as were the responses to aliskiren and irbesartan on day 14. RPF and GFR also 
showed an identical response to all 3 blockers, the glomerular response being somewhat 
larger than the RPF response. Captopril data for the groups that were subsequently treated 
with either irbesartan or aliskiren were combined since the responses to ACE inhibition were 
identical in both groups.
Plasma prorenin increased upon chronic irbesartan treatment only (Figure 2), and decreased 
upon acute exposure to aliskiren. Plasma renin increased acutely following captopril and 
aliskiren, but not following acute exposure to irbesartan. Plasma renin increased even further 
following chronic aliskiren exposure, and also increased following chronic treatment with 
irbesartan. However, plasma renin did not change on the 14th treatment day after either 
aliskiren or irbesartan application. PRA followed the renin pattern in the case of captopril 
and irbesartan, whereas in the case of aliskiren, PRA dropped dramatically, both acutely and 
on the 14th treatment day. Plasma Ang I rose, and plasma Ang II fell after acute exposure to 
captopril. Plasma Ang I and II fell acutely in response to aliskiren and fell again to near zero 
after dosing on day 14 of aliskiren (Figure 3). Conversely, Ang I and II levels did not change 
acutely in response to irbesartan, and increased significantly after chronic treatment. 
Application of irbesartan on the 14th treatment day did not change either plasma Ang I or 
Ang II. Serum aldosterone fell acutely with all 3 drugs. Its fall to irbesartan and aliskiren 
after two weeks was more modest than that on the first treatment day.
Discussion
The control of renal perfusion and function in the patient with diabetes mellitus is 
incompletely understood. Renin release from the kidney appears to be suppressed, although 
its local intrarenal action has a large effect on perfusion and function [1–4]. Prorenin is 
elevated in many patients. The 3 types of RAS blockers have large and divergent effects on 
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RAS parameters. This study was undertaken in the hope that the response to blockade at 
different levels would provide insight into the underlying renal control mechanism in the 
patient with diabetes mellitus.
Pharmacologic interruption of the RAS is complicated. In the case of ACE inhibitors, the 
response in part reflects a reduction in Ang II formation, but may well also include elements 
of bradykinin and nitric oxide pharmacology. In the case of ARBs, the accompanying rise in 
Ang II may result in Ang II type 2 (AT2) receptor stimulation, in the vessel wall as well as 
in the kidney [19–21]. Direct renin inhibition is, to date, pharmacologically clean, but we 
know very little about the local consequences of blockade at this level.
Previous studies have indicated that captopril induces its maximal RPF effect at a dose of 25 
mg [13], and that irbesartan induced a maximal response of the renal blood supply at a dose 
of 300 mg [14]. The maximal RPF response to aliskiren in normal subjects we reported was 
substantially larger than that to captopril and was achieved with a 600 mg dose [12], while 
maximal proteinuria reduction in type 2 diabetes patients occurred at 450 mg aliskiren [22]. 
We anticipated from data in our earlier study [12] that a 300 mg aliskiren dose would come 
close to inducing a response identical to that of captopril and irbesartan: we did, indeed, 
achieve an essentially identical acute renal (RPF, GFR) and blood pressure response to the 
three agents, facilitating comparison of the potentially responsible hormones. In addition, 
the acute effects of the 3 drugs at the level of the adrenal (resulting in an aldosterone 
reduction of 40–50%) were also identical.
Azizi et al. have argued that renin release in response to a pharmacologic antagonist 
provides an index of the effect of the antagonist on Ang II at the level of the renal 
juxtaglomerular AT1 receptor [8]. In this study our underlying hypothesis was that the 
renovascular response to blockade would provide a similar index. Surprisingly however, 
although comparable significant increases in RPF occurred with all 3 RAS blockers, this 
increase did not correlate at all with the rise in renin. The largest renin rise occurred with 
aliskiren. A more modest rise occurred following captopril, and no change at all was 
observed following acute exposure to irbesartan. Renin is the only RAS parameter that 
should consistently rise during RAS blocker treatment irrespective of the level at which 
blockade occurs - all other RAS parameters (PRA, Ang I and Ang II) will change in 
opposite directions. Indeed, PRA and Ang I rose with captopril, decreased with aliskiren and 
did not change with irbesartan, and Ang II decreased with captopril and aliskiren, while it 
was unaltered with irbesartan. Prorenin did not increase at all after acute blockade.
We next evaluated the chronic effect of RAS blockade, continuing treatment at the level of 
either renin or the AT1 receptor. The aliskiren-induced fall in PRA, Ang I and Ang II on first 
exposure was well sustained for two weeks, thus arguing against the concept of a massive 
renin rise overcoming the effect of renin inhibition [23–24]. Nevertheless, renin did increase 
further, reaching levels that were double those after acute exposure. It should be kept in 
mind that a substantial part of this ‘renin’ increase (up to 40% or more) represents prorenin 
bound to aliskiren, both acutely and chronically [17]. The underlying mechanism is that 
aliskiren binds to prorenin, thereby keeping prorenin in an ‘open’ renin-like conformation, 
allowing prorenin to be recognized as renin in a renin immunoradiometric assay (like the 
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Cisbio assay applied here). This aliskiren-to-prorenin binding simultaneously explains why 
prorenin decreased following acute exposure to aliskiren and why it did not rise following 
chronic aliskiren treatment. The latter usually occurs after chronic RAS blockade [5,25], like 
in the present study after chronic treatment with irbesartan. Such chronic AT1 receptor 
blocker treatment also increased, as expected, renin, PRA, Ang I and Ang II. The rise in 
renin was more modest than that observed after aliskiren. However, when taking into 
consideration the contribution of prorenin to the rise of renin after aliskiren, the renin rise 
after both drugs would have been comparable. Therefore, at least the long-term change in 
renin does reflect the equi-effectiveness of the two types of drugs at the level of the renal 
juxtaglomerular AT1 receptors.
Summarizing, plasma renin rises acutely in diabetics following blockade of Ang II 
formation with either captopril or aliskiren but not following blockade of AT1 receptors with 
irbesartan, although all three types of blockade did result in identical acute hemodynamic, 
renal and adrenal responses. The blunted acute renin response to irbesartan in diabetics has 
been noted before [1]. A further rise in plasma renin occurred following chronic treatment 
with either aliskiren or irbesartan, so that at least the chronic changes in renin did parallel 
the acute responses to RAS blockade, in agreement with the proposal by Azizi et al. [8]. 
This suggests that in diabetics a higher degree of AT1 receptor blockade needs to be 
accomplished at the level of the juxtaglomerular cells to affect renin release, which 
apparently only occurs upon prolonged treatment. This relative resistance points towards a 
high AT1 receptor receptor occupancy due to exceptionally high Ang II levels at that site, 
which can only be corrected acutely by drugs that suppress Ang II generation. However, 
when the RAS had been substantially upregulated following chronic RAS blocker treatment, 
aliskiren application on day 14 also no longer affected renin release, although it still induced 
substantial effects on blood pressure, RPF and GFR (comparable to the effects on day 1 of 
treatment). Its suppressing effects on aldosterone on day 14 were reduced by ~50%. 
Although the latter confirms that aldosterone release has become more Ang II-independent 
upon prolonged RAS blockade ‘aldosterone escape’, the lack of effect on renin release 
suggests that now inhibition of Ang II generation is also insufficient to affect renin release. 
This is not due to a lack of renin in the kidney, since renin levels in humans may easily rise 
100-fold [26]. Clearly therefore, at least in diabetics, renin release is relatively resistant to 
RAS blockade. Assuming that this reflects a high degree of AT1 receptor occupancy, e.g, as 
a consequence of an activated renal RAS, it appears that diabetics may require higher doses 
to fully block all renal effects of Ang II. Indeed, several trials have already indicated that the 
degree of RAS blockade required to treat diabetic nephropathy (i.e., to slow down or regress 
proteinuria) are substantially higher than those needed to induce hemodynamic effects [27–
29]. Importantly, such high doses are not required for all renal effects of Ang II, since the 
effects on RPF and GFR occurred acutely and repetitively with all RAS blockers to the same 
degree independently of changes in circulating renin. Clearly therefore, regional differences 
in Ang II levels exist in the diabetic kidney. In fact, the existence of such regional 
differences within the kidney is well-accepted [30–32]. The long-term rise in renin rather 
than the acute changes in RPF and GFR now may provide the best indication of the degree 
of blockade at the sites where the highest renal Ang II levels occur. In agreement with this 
concept, in patients with Type 2 diabetes, the reduction in albuminuria during RAS blocker 
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treatment correlated highly significantly with the rise in immunoreactive renin, i.e., the 
larger the rise in renin, the larger the reduction in urinary albumin excretion rate [27].
Given the elevated prorenin levels in diabetes, particularly when nephropathy is present, one 
possibility is that this increased renal Ang II production, at the site of the juxtaglomerular 
cell and elsewhere in the kidney, involves prorenin, e.g. via its activation through binding to 
the recently discovered prorenin receptor [18,33]. If so, the high plasma prorenin levels 
might be taken as a reflection of the activation of the renal RAS, and patients with high 
prorenin levels would then require higher RAS blocker doses. To answer this question, 
additional studies are required that involve patient treatment on the basis of their prorenin 
levels. If prorenin truly contributes to renal Ang II levels, renin inhibitors, being capable of 
blocking prorenin-dependent Ang I generation [18], seem the most appropriate drugs to 
block the renal RAS. The ongoing ALTITUDE trial, aimed at determining whether aliskiren 
on top of conventional RAS blockade reduces cardiovascular and renal morbidity and 
mortality, will address this issue [34].
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Hemodynamic and renal responses (maximum effect versus baseline) to acute (captopril, 
irbesartan, or aliskiren; open symbols) and chronic (irbesartan or aliskiren; closed symbols) 
RAS blockade in diabetic patients. Data are mean±SEM of n=21–43. #P<0.05 vs. t=0, 
*P<0.05 vs. acute application.
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Responses of prorenin, renin and PRA to acute (captopril, irbesartan, or aliskiren; open 
symbols) and chronic (irbesartan or aliskiren; closed symbols) RAS blockade in diabetic 
patients. Data are mean±SEM of n=21–43. #P<0.05 vs. t=0, *P<0.05 vs. acute application.
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Responses of Ang I, Ang II and aldosterone to acute (captopril, irbesartan, or aliskiren; open 
symbols) and chronic (irbesartan or aliskiren; closed symbols) RAS blockade in diabetic 
patients. Data are mean±SEM of n=21–43. #P<0.05 vs. t=0, *P<0.05 vs. acute application.
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Weight (kg) 101.4 ± 6.0 108.2 ± 5.7
Body mass index 34.8 ± 1.6 34.8 ± 1.7
HbA1c (%) 7.2 ± 0.2 7.6 ± 0.3
Fasting serum glucose (mg/dL) 122 ± 9 129 ± 8
Urine sodium (mmol/24 h) 271 ± 17 259 ± 21
Urine potassium (mmol/24 h) 68 ± 6 74 ± 7
Proteinuria # (%) 7 (33) 8 (36)
Renal plasma flow (mL/min/1.73m2) 414 ± 19 426 ± 13
Glomerular filtration rate (mL/min/1.73m2) 72 ± 3 67 ± 2
Prorenin (ng/L) 101 ± 20 111 ± 25
Renin (ng/L) 6.4 ± 1.0 12 ± 3.8
PRA (ng Ang I/ml per minute) 0.40 ± 0.08 0.72 ± 0.21
Ang I (pmol/L) 1.9 ± 0.4 2.9 ± 0.7
Ang II (pmol/L) 0.4 ± 0.1 0.7 ± 0.2
Aldosterone (ng/L) 92 ± 26 103 ± 20
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